Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck & Co., Inc
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A randomized study to assess efficacy and safety of Anaceptrapib when added to ongoing lipid-lowering therapy
1. Evaluate the efficacy of adding anacetrapib 100 mg for 52 weeks relative to placebo on plasma concentrations of LDL-C. 2. Evaluate the safety and tolerability of 52 weeks of treatment with anacetr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Inhaled Corticosteroid Plus Montelukast Compared with Inhaled Corticosteroid Therapy Alone in Patients with Chronic Asthma
1) To demonstrate that treatment with montelukast and mometasone, compared with mometasone alone, results in improvement in FEV1 in patients aged 15 to 85 years with chronic asthma; 2) To determine t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
Ensayo multicéntrico cruzado, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la tolerabilidad de rizatriptán 10 mg CBD en el tratamiento de la migraña aguda en pacientes que siguen un tratamiento profiláctico de la migraña con topiramato. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
To evaluate the efficacy of MK-0462 compared to placebo in the treatment of acute migraine in patients on topiramate for migraine prophylaxis, as measured by the proportion of treated attacks resultin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of V920 Ebola Vaccine in Healthy Adults Ensayo clínico de fase III, aleatorizado y controlado con placebo para evaluar la seguridad y la capacidad inmunógena de la vacuna contra el virus del Ébola V920) en adultos sanos
1-To determine whether vaccination with V920 from three separate consistency lots results in equivalent immunogenicity. 2- To determine the safety and tolerability of V920 from three Consistency Lot g...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period adaptive Crossover Polysomnography Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomnia
1. To evaluate the efficacy of MK-4305 compared with placebo in improving sleep efficiency (SE) as measured by polysomnography (PSG) on Night 1 and at the end of 4 weeks of treatment, where SE is defi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus
To evaluate the LDL-C lowering efficacy of ER niacin/laropiprant (1 to 2g) compared with placebo in patients with Type 2 diabetes.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients with Primary Insomnia- Study B
All Main/Primary objectives are MK-4305 high dose compared to placebo, as measured by change from baseline: Maintenance- 1. Mean subjective total sleep time (sTSTm) at Month 1 2. Wakefulness after p...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia
In patients with primary hypercholesterolemia or mixed hyperlipidemia, evaluate: The LDL-C lowering efficacy of MK-0524B 2g (pooled across simvastatin doses of 20 and 40 mg) compared to MK-0524A 2g.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind Study of MK-0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Main objective : In patients with type 2 diabetes mellitus with inadequate glycemic control on diet and exercise: (1) After 18 weeks, to assess the effect of treatment with MK-0431 compared with ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
A phase IIb study of ridaforolimus, dalotzumab and exemestane in combination in advanced breast cancer
The primary objective of the study is to evaluate the progression free survival (PFS) for the triplet combination of ridaforolimus, dalotuzumab and exemestane (R/D/E) compared to the combination of ri...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant